Literature DB >> 21807015

Contact sensitizers modulate the arachidonic acid metabolism of PMA-differentiated U-937 monocytic cells activated by LPS.

Aurélia Del Bufalo1, José Bernad, Christophe Dardenne, Denis Verda, Jean Roch Meunier, Françoise Rousset, Silvia Martinozzi-Teissier, Bernard Pipy.   

Abstract

For the effective induction of a hapten-specific T cell immune response toward contact sensitizers, in addition to covalent-modification of skin proteins, the redox and inflammatory statuses of activated dendritic cells are crucial. The aim of this study was to better understand how sensitizers modulate an inflammatory response through cytokines production and COX metabolism cascade. To address this purpose, we used the human monocytic-like U-937 cell line differentiated by phorbol myristate acetate (PMA) and investigated the effect of 6 contact sensitizers (DNCB, PPD, hydroquinone, propyl gallate, cinnamaldehyde and eugenol) and 3 non sensitizers (lactic acid, glycerol and tween 20) on the production of pro-inflammatory cytokines (IL-1β and TNF-α) and on the arachidonic acid metabolic profile after bacterial lipopolysaccharide (LPS) stimulation. Our results showed that among the tested molecules, all sensitizers specifically prevent the production of PMA/LPS-induced COX-2 metabolites (PGE(2,) TxB(2) and PGD(2)), eugenol and cinnamaldehyde inhibiting also the production of IL-1β and TNF-α. We further demonstrated that there is no unique PGE(2) inhibition mechanism: while the release of arachidonic acid (AA) from membrane phospholipids does not appear do be a target of modulation, COX-2 expression and/or COX-2 enzymatic activity are the major steps of prostaglandin synthesis that are inhibited by sensitizers. Altogether these results add a new insight into the multiple biochemical effects described for sensitizers.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21807015     DOI: 10.1016/j.taap.2011.06.025

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  5 in total

1.  Novel neuroprotective GSK-3β inhibitor restricts Tat-mediated HIV-1 replication.

Authors:  Irene Guendel; Sergey Iordanskiy; Rachel Van Duyne; Kylene Kehn-Hall; Mohammed Saifuddin; Ravi Das; Elizabeth Jaworski; Gavin C Sampey; Svetlana Senina; Leonard Shultz; Aarthi Narayanan; Hao Chen; Benjamin Lepene; Chen Zeng; Fatah Kashanchi
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

2.  Synthesis and anti-inflammatory activity of novel triazole hybrids of (+)-usnic acid, the major dibenzofuran metabolite of the lichen Usnea longissima.

Authors:  Nagi Reddy Vanga; Anudeep Kota; Ramakrishna Sistla; Mallavadhani Uppuluri
Journal:  Mol Divers       Date:  2017-01-27       Impact factor: 2.943

3.  Inhibitions of NF-κB and TNF-α result in differential effects in rats with acute on chronic liver failure induced by d-Gal and LPS.

Authors:  Fan Yang; Xun Li; Li-Kun Wang; Lu-Wen Wang; Xiao-Qun Han; Hong Zhang; Zuo-Jiong Gong
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

4.  LRH-1 mediates anti-inflammatory and antifungal phenotype of IL-13-activated macrophages through the PPARγ ligand synthesis.

Authors:  Lise Lefèvre; Hélène Authier; Sokrates Stein; Clarisse Majorel; Bettina Couderc; Christophe Dardenne; Mohamad Ala Eddine; Etienne Meunier; José Bernad; Alexis Valentin; Bernard Pipy; Kristina Schoonjans; Agnès Coste
Journal:  Nat Commun       Date:  2015-04-15       Impact factor: 14.919

5.  Cisplatin protects against acute liver failure by inhibiting nuclear HMGB1 release.

Authors:  Xun Li; Li-Kun Wang; Lu-Wen Wang; Xiao-Qun Han; Fan Yang; Zuo-Jiong Gong
Journal:  Int J Mol Sci       Date:  2013-05-27       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.